Who Owns XLO?

Xilio Therapeutics, Inc. — Institutional Ownership & 13F Holdings

$8.29

-0.02 (-0.24%)

Market Cap

$28.4M

Shares Outstanding

5,782,511

Institutional Holders

34

Total Inst. Value

$15.2M

% of Float Held

QoQ Holder Change

+6

Institutional data as of Q1 2025

New Positions

8

Closed Positions

8

Increased

8

Decreased

7

Institutional Ownership Trend

Top 10 Institutional Holders(Q1 2025)

#FundValueShares
1GILEAD SCIENCES, INC.$6.6M9,105,451
2Bain Capital Life Sciences Investors, LLC$3.3M4,566,817
3Merck & Co., Inc.$1.1M1,483,758
4MORGAN STANLEY$836K1,155,838
5VANGUARD GROUP INC$822K1,135,716
6FMR LLC$640K884,035
7AJU IB Investment Co., Ltd.New$484K667,742
8GEODE CAPITAL MANAGEMENT, LLC$273K379,016
9BALYASNY ASSET MANAGEMENT L.P.$184K254,346
10Trustees of Columbia University in the City of New York$181K249,635

Biggest Buyers & Sellers This Quarter

Top Buyers

Top Sellers

Famous Fund Managers

Related Stocks

Frequently Asked Questions

How many institutional investors hold XLO?

As of Q1 2025, 34 institutional investors report holding XLO (Xilio Therapeutics, Inc.) in their 13F filings.

Which hedge fund owns the most XLO?

The largest institutional holder of XLO is GILEAD SCIENCES, INC. with $6.6M in shares.

Are institutions buying or selling XLO?

This quarter, 8 institutions opened new positions in XLO and 8 closed their positions.

What is 13F institutional ownership?

SEC Form 13F is a quarterly report filed by institutional investment managers with over $100M in qualifying assets. It discloses their US equity holdings, providing transparency into what the largest investors are buying and selling.

How often is institutional ownership data updated?

13F filings are due 45 days after each calendar quarter end (May 15, Aug 14, Nov 14, Feb 14). Data is updated on HedgeTrace as new filings are processed.